



David Twum-Barima MBCHB, MSC, FRCPC

* David Twum-Barima provides medical services through Dr. David Y. Twum Barima Medicine Professional Corporation

Oakville 3075 Hospital Gate, Suite 301, Oakville, Ontario, L6M 1M1, Canada Tel (905) 337-0040

CURRICULUM VITAE

Education, Certification & Licenses

2019-2021	ICH-GCP Certification	Syneos Health
1983-1984	Certification & Fellowship, Internal Medicine	Fellow, Royal College of Physicians Canada
1983-1984	Sub-specialty Training in Endocrinology and Metabolism	Ottawa Civic Hospital, Ottawa ON
1979-1981	Master of Science	University of Western Ontario, London ON
1969-1974	Bachelor of Medicine	University of Ghana, Ghana

Professional Activities

2002-Present	Principal Investigator	LMC Clinical Research Inc.
2002-Present	Associate Endocrinologist	LMC Diabetes & Endocrinology
2002	Emergency Specialty Relief Staff	North York General Hospital, Toronto ON
1994-2002	Chief of Medicine	Quinte Health Care Corporation, Trenton Memorial Site, Trenton ON
1992-1996	Director, Continued Medical Education	Trenton Memorial Hospital, Trenton ON
1989-2002	Active Staff, Department of Medicine	Belleville General Hospital, Belleville ON
1989-1992	Director, Intensive Care Unit	Trenton Memorial Hospital, Trenton ON
1985-1988	Lecturer, Faculty of Medicine and Endocrinology	University of Manitoba, Winnipeg MB
1984-1988	Consultant Internal Medicine and Endocrinology	Winnipeg, Manitoba
1985-1988	Consultant, Internal Medicine	Health Sciences Centre, Winnipeg, MB
1985-1988	Active Staff	Victoria General Hospital, Winnipeg MB

Achievements, Associations & Specialties

Publications	Twum-Barima, Y. , A Study of central respiratory effects of four beta-adrenergic blocking drugs: MSc Thesis, University of Western Ontario, April, 1981 Twum-Barima, Y. , and Carruthers, S. G., Quinidine-Rafampin Interaction. New England Journal of Medicine 304 (24) 1466-1469, 1981 Twum-Barima, Y. , Ahmad, D., Hamilton, J. T. and Carruthers, S. G., Lack of effect of beta-adrenergic blocking drugs on the hyperventilatory response to carbon dioxide in normal subjects. Clinical Pharmacology and Therapeutics, 32: 289-294, 1982 Carruthers SG, Twum-Barima, Y. , Measurements of Partial Agonist Activity of Pindolol in Man. Clinical Pharmacology & Therapeutics, 30:581-6, 1981 Klein, G. J., Twum-Barima, Y. , Gulamhusein, S., Carruthers, S.G., Jarvis, R.T. and Doner, A.P., Ph.D. Verapamil in Chronic Atrial Fibrillation: Pharmacokinetics and variable Patterns of Response, Clin. Cardiol. 7, 474-483, 1984 Twum-Barima Y. , Carruthers SG Assessment of agonist activity of pindolol by evaluation of metoprolol-pindolol interaction. Clin Res 28(3), 667A, 1980 Twum-Barima Y. , Ahmad D, McCall B, Carruthers SG. Cardiac & respiratory effects of 4 beta-adrenoceptor blocking drugs. Clin Res 28(3) 667A, 1980
Awards	Astra Award for Best Presentation by Trainee in Clinical Pharmacology, Canadian Society for Clinical Pharmacology and Therapeutics, 1980
Memberships	Canadian Diabetes Association (CDA) American Diabetes Association (ADA) The Canadian Society of Endocrinology and Metabolism (CSEM)

Clinical Trials & Research Activities

2010-2020	BC22092 (Roche), H9X-MC-GBCF (Eli Lilly), EFC10781 (Sanofi-aventis), H9X-MC-GBDN (Eli Lilly), D1690C00019 (AstraZeneca), R331333PAI3027 (J&J), SYR-332-305 (Takeda), 20080099 (Amgen), CLAF2224 (Novartis), 1001 (Andromeda), CACZ88512207 (Novartis), 28431754DIA3010 (J&J), TRX4_DM_017_CAN_10 (Tolerx), H9X-MC-GBDJ (Eli Lilly), TRX4_DM_008_WW_10 (Tolerx), 1218.23 (BI), DAPA06 Ext (AstraZenca), TAK-875_306 (Takeda), I2R-MC-BIAJ (Eli Lilly), TAK-875_304 (Takeda), EFC12347 (Sanofi-aventis), D1693C00001 (AstraZeneca), MK8835-002 (Merck), NN9211-3919 (Novo Nordisk), B1481022 (Pfizer), B1481038 (Pfizer), B1481045 (Pfizer), 28431754DIA2004 (Janssen), APD356-G000-401 (Eisai), 200977 (GSK), D1690C00024 (AstraZeneca), D5881C00004 (AstraZeneca), LX4211.312 (Lexicon), MK-0431-845 (Merck), NN1218-3854 (Novo Nordisk), GOAL-RCT (LMC), LPS14347 (Sanofi), EFC14834 (Sanofi), MSC15146 (Sanofi), NN1250-4252 (Novo Nordisk), K-877-302 (Kowa), NN1250-4419 (Novo Nordisk), LPS15544 (Sanofi), EFC14828 (Sanofi), NN9535-4352 (Novo Nordisk), I8B-MC-ITRO (Eli Lilly), REMIT iDeglira (PHRI), , etc.
2002-2009	DJN608B2302 (Novartis), MK-0431-052 (Merck), A2171022 (Pfizer), EFC5826 (Sanofi-aventis), EFC4736 (Sanofi-aventis), SYR-475-022 (Takeda), LPL100601 (GSK), B0341001 (Pfizer), P015/MD-11a-10945 (Dr. Reddy's), EFC4735 (Sanofi-aventis), H3S-MC-GGIO (Eli Lilly), PO1418 (Schering), D1690C00006 (AstraZeneca), LANTU C 50079 (Sanofi-aventis), E2007-G000-227 (Eisai), E2007-G000-228 (Eisai), CL3-05702-013 (Servier), 1218.18 (BI), MB102-014 (BMS), CSPP100E2337 (Novartis), NN 1250SIBA (Novo Nordisk), A2171121 (Pfizer), R331333-PAI-3015 (J&J), MB102013(AstraZeneca), MB102-013 (BMS), SA 10780 (Sanofi-aventis), 20080099 (Amgen), TRX4_DM_013_CAN_09 (Tolerx), BC21893A (Roche), CLAF237B2201 (Novartis), AVD11196 (GSK), 1218.52 (BI), AXON-201 (TransTech Pharma), DM 200-101 (ConjuChem), 1218.40 (BI), 1218.46 (BI), SA 6910 (Sanofi-Aventis), CLAF237A2308 (Novartis), A5351025 (Pfizer), CL-503011 (Bellus), CV181-011 (BMS), CV181-014 (BMS), etc.